Mito-TEMPO (Standard)
Mito-TEMPO (Standard) is the analytical standard of Mito-TEMPO (HY-112879). This product is intended for research and analytical applications. Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/ParKin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic Kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
For research use only. We do not sell to patients.
- CAS No.: 1334850-99-5
- Formula: C29H35ClN2O2P
- Molecular Weight:510.03
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1334850-99-5
-
Molecular Weight 510.03
-
Formula C29H35ClN2O2P
-
SMILES
[O]N1C(C)(C)CC(NC(C[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)=O)CC1(C)C.[Cl-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Liu B, et al. MitoTEMPO protects against podocyte injury by inhibiting NLRP3 inflammasome via PINK1/Parkin pathway-mediated mitophagy. Eur J Pharmacol. 2022;929:175136. [Content Brief]
[2]. Olgar Y, et al. MitoTEMPO provides an antiarrhythmic effect in aged-rats through attenuation of mitochondrial reactive oxygen species. Exp Gerontol. 2020;136:110961. [Content Brief]
[3]. Li J, et al. Mitochondria-specific antioxidant MitoTEMPO alleviates senescence of bone marrow mesenchymal stem cells in ovariectomized rats. J Cell Physiol. 2024;239(8):e31323. [Content Brief]
[4]. Akkoca A, et al. Protective effect of MitoTEMPO against cardiac dysfunction caused by ischemia-reperfusion: MCAO stroke model study. Int J Neurosci. 2024;134(12):1582-1593. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mito-TEMPO (Standard) Related Classifications
HY-112879R Related Classifications
Powered by Bioz
Keywords
- Mito-TEMPO (Standard)
- 1334850-99-5
- NOD-like Receptor (NLR)
- Mitochondrial Metabolism
- Reference Standards
- Apoptosis
- Calcium Channel
- Autophagy
- PINK1/Parkin
- NLRP3 inflammasome
- chronic kidney disease
- mitochondrial ROS
- ischemic stroke
- mitophagy
- rat BMSCs
- Parkin
- human podocyte cells
- PINK1/Parkin pathway
- postmenopausal osteoporosis
- Inhibitor
- inhibitor
- inhibit